The phenomenon whereby the presence of oxygen regulates the rate of glucose metabolism was first described by Louis Pasteur. A novel mechanism has now been discovered, involving the AMP-activated protein kinase cascade, that can account for the Pasteur effect in ischaemic heart muscle. In 1861 Louis Pasteur [1] reported that oxygen inhibits fermentation, the production of ethanol by glycolysis in yeast. The corollary of this is that anoxia, the absence of oxygen, stimulates glycolysis. This phenomenon, which occurs in mammalian cells as well as yeast, became known as the 'Pasteur effect', and it took a whole century for the first mechanism that can account for it to be elucidated. Important clues came in the 1930s and 1940s, from studies of mysterious deaths among workers who handled picric acid (trinitrophenol) in the explosives industry, and who suffered from acute elevation of body temperature. It turned out that nitrophenols 'uncouple' phosphorylation from respiration, allowing respiration to continue without the resynthesis of ATP from ADP, the energy being dissipated instead as heat. In the presence of these uncoupling agents the Pasteur effect was found to be abolished, with glycolysis occurring at a high rate in the presence or absence of oxygen.
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With the benefit of hindsight, one obvious explanation of the Pasteur effect is that the adenine nucleotides themselves control glycolysis. The final link was the finding by Passonneau and Lowry [2] and others in the early 1960s that the glycolytic enzyme phosphofructokinase is allosterically activated by AMP, and that this is antagonized by high concentrations of ATP. At first sight it might seem more logical for ADP, rather than AMP, to regulate phosphofructokinase. But because of the near equilibrium of the reaction catalysed by adenylate kinase in most cells -2ADP ↔ ATP + AMP -a small increase in the ADP:ATP ratio is amplified into a much larger increase in AMP:ATP ratio (if the adenylate kinase reaction is at equilibrium, the AMP:ATP ratio will vary as the square of the ADP:ATP ratio, making the former a much more sensitive indicator of cellular energy status). This is the 'classical' explanation for the Pasteur effect: in the absence of oxygen, ATP production falls, the AMP:ATP ratio rises and phosphofructokinase, and hence glycolysis, will be stimulated.
Although more recent studies have shown that the control of glycolysis is distributed across several steps, and is not solely confined to phosphofructokinase, this remains the explanation given in most textbooks and introductory courses in biochemistry. While it remains valid, and may indeed be a reasonably complete explanation for the Pasteur effect in some cell types, in this issue of Current Biology, Hue and coworkers [3] report a novel additional mechanism to account for the Pasteur effect in ischaemic heart muscle.
In the early 1980s, Hue and others [4] discovered a new allosteric activator of phosphofructokinase -fructose-2,6-bisphosphate. Fructose-2,6-bisphosphate is formed from fructose-6-phosphate and ATP ( Figure 1 ) by an enzyme called 6-phosphofructo-2-kinase. This enzyme catalyzes a very similar reaction to phosphofructokinase, but attaches the phosphate to carbon-2 of fructose-6-phosphate, rather than carbon-1 (strictly, the glycolytic enzyme should be called 6-phosphofructo-1-kinase). Fructose-2,6-bisphosphate is not a metabolic intermediate but a signal molecule, the only known fate of which is hydrolysis back to fructose-6-phosphate, catalyzed by fructose-2,6-bisphosphatase. Intriguingly, the 6-phosphofructo-2-kinase and fructose-2,6-bisphosphatase reactions are catalyzed by distinct domains of a single, bifunctional polypeptide. In mammals this bifunctional enzyme occurs as at least four distinct isoforms that have distinct regulatory properties.
At this point a new player, the AMP-activated protein kinase (AMPK) [5] , enters the story. As well as phosphofructokinase, certain other metabolic enzymes, such as glycogen phosphorylase, are also regulated by AMP, ADP and/or ATP, and in the 1960s Daniel Atkinson [6] proposed that most, if not all, branch points between anabolism and catabolism might be controlled by these nucleotides. This became known as the 'adenylate control' or 'energy charge' hypothesis. The latter term came from the analogy between ATP and ADP and the chemicals in an electrical cell or battery. A high ATP:ADP ratio represents a fully charged battery, while a low ratio represents a discharged or 'flat' battery. Atkinson's idea perhaps lost some support during the 1970s and 1980s because, after the first examples, few other metabolic enzymes were found to be directly regulated by adenine nucleotides. Nevertheless it can be argued that his proposal was correct, but that he had not anticipated the complete mechanism by which it operates.
AMPK now appears to be the primary sensor of cellular energy charge [5] , and most of the effects of ATP depletion are probably mediated through this kinase pathway, rather than through direct effects of adenine nucleotides on proteins producing the final output. AMPK is phosphorylated and activated by at least one upstream kinase (AMPKK), and increases in AMP activate this cascade via a complex mechanism that makes it exquisitely sensitive to small changes in the AMP:ATP ratio [7] . AMPK is therefore activated by cellular stresses that either inhibit ATP production -as do heat shock, uncouplers or other metabolic poisons, deprivation of oxygen or glucose -or stimulate ATP consumption -as exercise does in muscle. The activated kinase switches on catabolic pathways that generate ATP, while switching off anabolic pathways and other processes that consume ATP. It achieves this both acutely, via direct phosphorylation of metabolic enzymes, and chronically, via effects on gene expression.
Hue's group [3] has now identified a new target for AMPK: the heart isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. AMPK phosphorylates this bifunctional enzyme at a single site, serine 466, resulting in an increase in the V max of the 6-phosphofructo-2-kinase activity, without affecting the fructose-2,6-bisphosphatase activity. A mutant form of the enzyme, S466E, in which serine 446 is replaced by a negatively charged glutamate, mimicking phosphorylation, is constitutively active and is not a substrate for AMPK. The sequence around serine 466 is a reasonable, if not exact, fit to the proposed consensus recognition motif for AMPK substrates [8] , and the site appears to be phosphorylated with kinetic parameters only slightly inferior to those of acetylCoA carboxylase, an established physiological substrate.
Marsin et al. [3] went on to show that this phosphorylation is physiologically relevant and occurs in the heart during ischaemia -interruption of the blood supply to the heart muscle, which is what happens during a heart attack. AMPK is transiently activated by ischaemia in isolated, perfused rat hearts, peaking at 10-fold activation after 10 minutes, and then declining over the next 20 minutes. Given that ischaemia is known to cause elevation of the AMP:ATP ratio in the heart, this effect is not surprising, although the reason for its transient nature remains unclear. It may be that after prolonged, severe ischaemia the ATP levels become so low that they can no longer support the ATP requirement of the AMPK cascade itself. Marsin et al. [3] also found that the AMPK activation correlates excellently with transient three-fold increases in both 6-phosphofructo-2-kinase activity and the cellular content of its product, fructose-2,6-bisphosphate. This also correlates with previous studies on the rate of glycolysis, which during prolonged ischaemia is also transiently activated, followed by a marked decline. It should be emphasized that AMPK activation has also been reported to stimulate translocation of the glucose transporter GLUT-4 to the plasma membrane and consequent glucose uptake in heart [9] , and this effect may also contribute to the stimulation of glycolysis.
The new mechanism was further tested [3] using transfected HEK-293 cells expressing the heart isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Activation of endogenous AMPK using the respiratory chain inhibitor oligomycin resulted in a two-fold activation of 6-phosphofructo-2-kinase, but not of an S466E mutant form of the enzyme. Expression of a kinase-inactive mutant form of the α1 subunit of AMPK blocked the effect of oligomycin on both activation of 6-phosphofructo-2-kinase and the phosphorylation of serine 466. In these Mechanism of activation of glycolysis by AMP-activated protein kinase (AMPK) in heart muscle. Inhibition of respiration by hypoxia or oligomycin in turn inhibits the synthesis of ATP from ADP + Pi. As contraction of the heart, converting ATP to ADP + Pi, continues, the ADP:ATP ratio will rise. This is amplified into a larger rise in the AMP:ATP ratio by adenylate kinase, and this in turn activates AMPK via the established mechanism [7] . AMPK phosphorylates 6-phosphofructo-2-kinase (6PF2K) leading to an increase in fructose-2,6-bisphosphate (F26BP). This signal stimulates phosphofructokinase and hence glycolysis -the Pasteur effectresulting in anaerobic production of ATP to meet the shortfall. Glycolysis is also stimulated due to effects of AMPK on GLUT4 translocation [9] . Black text is reserved for metabolites (the names of enzymes and other proteins are shown in blue); the black arrows represent metabolic transformations; green and red arrows represent regulatory circuits, green for activation and red for inhibition. cells, the kinase-inactive form of AMPK appears to act as a dominant-negative mutant -probably by competing for the regulatory β and γ subunits of AMPK -because it also blocked activation of both endogenous and transfected AMPK by oligomycin. This shows that activation of AMPK is necessary, as well as sufficient, for the effect of oligomycin on 6-phosphofructo-2-kinase.
The liver and skeletal muscle isoforms of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase lack the carboxy-terminal sequence with the consensus AMPK site, so this mechanism would only be expected to operate in cells expressing the heart isoform -heart and kidney. This perhaps makes sense in liver, where fructose-2,6-bisphosphate also regulates gluconeogenesis, and where glycolysis can be regarded as an anabolic rather than a catabolic pathway (for example, it provides precursors for lipid biosynthesis). It is less clear, however, why this mechanism should not operate in skeletal muscle. Glucose uptake is still activated by AMPK in that tissue, and 6-phosphofructo-1-kinase would still be allosterically regulated by AMP and ATP (the classical explanation for the Pasteur effect). Perhaps those controls are sufficient in skeletal muscle.
Finally, in the 1920s Warburg reported that many tumour cells have a high rate of glycolysis (tumours often having a poor blood supply in vivo). Some tumours overexpress a placental isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase [10] in which the AMPK phosphorylation site is conserved. Although they did not test the placental enzyme itself, Marsin et al. [3] did examine a synthetic peptide based on this sequence, which was indeed a substrate for AMPK. This raises the intriguing possibility that AMPK, and its phosphorylation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase, could be helping to keep some hypoxic tumours alive until they have established a new blood supply.
